This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG.Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. PharmacoEconomics 25: 963-977, No. 11, 2007
Rights and permissions
About this article
Cite this article
Entecavir of benefit in HBeAg-positive Hep B. Pharmacoecon. Outcomes News 542, 9 (2007). https://doi.org/10.2165/00151234-200705420-00018
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705420-00018